Portugal

Pharmaceuticals will have to ensure free treatment after testing

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 23/10/2026, 10:50:25 UTC.

Briefings

The evidence indicates that pharmaceutical companies will be legally required to provide free treatment to patients after clinical trials, regardless of whether the drugs reach the market or the National Health Service. This represents a significant shift in post-trial obligations, ensuring access even if commercialization delays occur.

Key points

• Pharmaceutical companies are legally obligated to provide free treatment to patients after clinical trials, regardless of whether the drugs reach the market or the National Health Service.
• The obligation applies to all patients post-trial, creating a new pathway for access that bypasses standard market entry requirements.

Context

This finding establishes a mandatory post-trial access mechanism, ensuring patients receive care even if commercialization delays occur.

Limitations

The evidence is limited to the specific legal obligation; it does not specify the duration of the post-trial period, the exact number of patients affected, or the specific conditions under which access is guaranteed.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 23/10/2026, 12:02:03 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeiagx5fpamlqfp2wjq2hmmrz7s2zwjcqbdluz4xmybglejmkryx7my